China Pharma (CPHI) vs TransCode Therapeutics (RNAZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
China Pharma (CPHI) has outperformed TransCode Therapeutics (RNAZ) over the past year, losing 72.6% versus a loss of 86.6%. Over five years, CPHI leads with a -99.8% price change compared with -100.0% for RNAZ. TransCode Therapeutics is the larger company by market cap ($20.1 million vs $18.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPHI | RNAZ |
|---|---|---|
| Share price | $0.4384 | $1.16 |
| Market cap | $18.86M | $20.07M |
| 1-day change | -13.00% | -10.77% |
| YTD return | -63.77% | -83.02% |
| 1-year return | -72.60% | -86.57% |
| 5-year return | -99.84% | -100.00% |
| EPS (TTM) | $-0.42 | $-47.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.14M | — |
| Revenue growth (YoY) | -8.49% | — |
| Net income (latest FY) | $-3.19M | $-34.66M |
| Gross margin | -3.18% | — |
| Operating margin | -78.16% | — |
| Net margin | -76.91% | — |
| 52-week high | $19.19 | $12.60 |
| 52-week low | $0.38 | $1.01 |
| Distance from 52-week high | -97.72% | -90.79% |
| Average volume | 1.60M | 52.03K |
| Shares outstanding | 43.02M | 17.30M |
| Employees | 215 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CPHI has outperformed RNAZ by 14.0 percentage points over the past year.
About China Pharma
CPHI stock →China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.
Health Care · Biotechnology: Pharmaceutical Preparations · 215 employees
About TransCode Therapeutics
RNAZ stock →TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
CPHI vs RNAZ FAQ
Which is bigger, China Pharma or TransCode Therapeutics?
TransCode Therapeutics (RNAZ) is larger, with a market capitalization of $20.07M compared with $18.86M for China Pharma (CPHI).
Which stock has performed better over the past year, CPHI or RNAZ?
CPHI returned -72.60% over the past 12 months, compared with -86.57% for RNAZ (price return, excluding dividends). Past performance does not predict future results.
Are China Pharma and TransCode Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.